Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pal Miheller

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Expert Review of Clinical Immunology|December 22, 2012
Recommendations for identifying Crohn's disease patients with poor prognosisPal Miheller, Lajos S Kiss, Mark Juhasz, et al.
Digestive Diseases (Basel, Switzerland)|June 28, 2014
Have biologics changed the natural history of Crohn's disease?Michael D Mandel, Pal Miheller, Katalin Müllner, et al.
Cytometry. Part B, Clinical Cytometry|September 16, 2006
Automated virtual microscopy of gastric biopsiesLevente Ficsor, Viktor Varga, Lajos Berczi, et al.
Expert Opinion on Biological Therapy|May 10, 2023
Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease: results of a multicenter surveyPatrícia Sarlós, Alexander Bikar, Nelli Farkas, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 5, 2022
Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease - a prospective, multicentre studyLivia Lontai, Lorant Gonczi, Fruzsina Balogh, et al.
Digestive Diseases and Sciences|August 22, 2008
The 3'UTR NFKBIA variant is associated with extensive colitis in Hungarian IBD patientsTamas Szamosi, Peter Laszlo Lakatos, , et al.
The Lancet. Gastroenterology & Hepatology|October 8, 2020
Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trialRaja Atreya, Laurent Peyrin-Biroulet, Andrii Klymenko, et al.
Journal of Crohn'S & Colitis|December 3, 2010
Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel diseasePeter Laszlo Lakatos, Zsofia Czegledi, Gyula David, et al.
The American Journal of Gastroenterology|December 1, 2007
New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohortMaria Papp, Istvan Altorjay, Nir Dotan, et al.
World Journal of Gastroenterology|November 5, 2010
NKX2-3 and IRGM variants are associated with disease susceptibility to IBD in Eastern European patientsNora Meggyesi, Lajos S Kiss, Magdalena Koszarska, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Expert Review of Clinical Immunology|December 22, 2012
Recommendations for identifying Crohn's disease patients with poor prognosisPal Miheller, Lajos S Kiss, Mark Juhasz, et al.
Digestive Diseases (Basel, Switzerland)|June 28, 2014
Have biologics changed the natural history of Crohn's disease?Michael D Mandel, Pal Miheller, Katalin Müllner, et al.
Cytometry. Part B, Clinical Cytometry|September 16, 2006
Automated virtual microscopy of gastric biopsiesLevente Ficsor, Viktor Varga, Lajos Berczi, et al.
Expert Opinion on Biological Therapy|May 10, 2023
Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease: results of a multicenter surveyPatrícia Sarlós, Alexander Bikar, Nelli Farkas, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 5, 2022
Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease - a prospective, multicentre studyLivia Lontai, Lorant Gonczi, Fruzsina Balogh, et al.
Digestive Diseases and Sciences|August 22, 2008
The 3'UTR NFKBIA variant is associated with extensive colitis in Hungarian IBD patientsTamas Szamosi, Peter Laszlo Lakatos, , et al.
The Lancet. Gastroenterology & Hepatology|October 8, 2020
Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trialRaja Atreya, Laurent Peyrin-Biroulet, Andrii Klymenko, et al.
Journal of Crohn'S & Colitis|December 3, 2010
Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel diseasePeter Laszlo Lakatos, Zsofia Czegledi, Gyula David, et al.
The American Journal of Gastroenterology|December 1, 2007
New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohortMaria Papp, Istvan Altorjay, Nir Dotan, et al.
World Journal of Gastroenterology|November 5, 2010
NKX2-3 and IRGM variants are associated with disease susceptibility to IBD in Eastern European patientsNora Meggyesi, Lajos S Kiss, Magdalena Koszarska, et al.
Pageof 3